Market Overview:
The global generic active pharmaceutical ingredients (APIs) market is expected to grow at a CAGR of 6.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for generics due to their cost-effectiveness and rising prevalence of chronic diseases. In addition, the increasing number of blockbuster drugs going off-patent is also contributing to the growth of this market. The monoclonal antibodies segment is expected to account for the largest share of the global generic APls market in 2018, followed by hormones, cytokines, fusion proteins, therapeutic enzymes, vaccines and blood factors segments. The oncology application segment is expected to account for the largest share of this market in 2018 followed by diabetes and cardiovascular disease applications segments.
Product Definition:
Generic Active Pharmaceutical Ingredients are the chemical compounds that are used in the manufacture of pharmaceutical products. These substances are responsible for the therapeutic effects of medications, and they must meet certain quality standards in order to be approved by regulatory agencies. Generic Active Pharmaceutical Ingredients allow for the production of low-cost generic medications, which can help to improve access to healthcare for millions of people around the world.
Monoclonal Antibodies:
Monoclonal antibodies are also known as monoclonal proteins. They are antibody molecules, which are produced by the body's immune system specifically targeting and binding to a specific harmful cell or tissue. The most common application of monoclonal antibodies is in cancer treatment where they can target and attach themselves to any part of the cancer cells that would then cause them to die.
Hormones:
Hormones and its usage in generic active pharmaceutical ingredients market is expected to grow at a lucrative rate during the forecast period. The growth of this market can be attributed to factors such as rising prevalence of hormone-related disorders, increasing demand for bio-based products, and growing awareness among consumers regarding Hormone Replacement Therapy (HRT).
Application Insights:
The others segment includes infectious diseases, nephrological disease, respiratory disorders, skin and tissue disorder and musculoskeletal disorders. The Others segment held the largest share of the global market in 2017. This is due to a large number of drugs developed for various purposes such as anxiety treatment, weight reduction programs etc. Thus this application category is expected to grow at a lucrative rate during the forecast period owing to an increasing number of drug candidates for different applications in this field.
Oncology was one of the leading segments that accounted for more than 25% share in 2017 owing to high incidence rates associated with cancer worldwide coupled with rising awareness about oncology drugs among patients globally.
Regional Analysis:
North America dominated the global market in 2017. The growth of this region can be attributed to factors such as increasing prevalence of chronic diseases, rising healthcare expenditure, and presence of key players in this region. Moreover, high adoption rate for advanced therapeutics is also expected to drive the regional market over the forecast period.
Asia Pacific is anticipated to witness lucrative growth during the forecast period owing to rise in disposable income and improving healthcare infrastructure coupled with growing awareness about advanced therapeutics among patients. Furthermore, increase in number of clinical trials conducted for new drug development will boost product launches which will further propel demand over next eight years time frame.
In 2016 Novo Nordisk along with other companies invested around USD X million on research & development activities pertaining their business units that include diabetes care.
Growth Factors:
- Increasing demand for generic drugs due to their low cost and efficacy as compared to branded drugs
- Rising incidence of chronic diseases such as cancer, diabetes, and heart diseases that require long-term treatment
- Growing awareness about the benefits of using generic drugs among healthcare professionals and patients
- Proliferation of online pharmacies that offer a wide range of generic drugs at competitive prices
- Stringent regulations by the FDA and other regulatory bodies aimed at ensuring the quality and safety of generic drugs
Scope Of The Report
Report Attributes
Report Details
Report Title
Generic Active Pharmaceutical Ingredients Market Research Report
By Type
Monoclonal Antibodies, Hormones, Cytokines, Fusion Proteins, Therapeutic Enzymes, Vaccines, Blood Factors
By Application
Oncology, Diabetes, Cardiovascular Disease, CNS and Neurological Disorders, Endocrinology, Others
By Companies
Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), Pfizer, Inc. (U.S.)
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
189
Number of Tables & Figures
133
Customization Available
Yes, the report can be customized as per your need.
Global Generic Active Pharmaceutical Ingredients Market Report Segments:
The global Generic Active Pharmaceutical Ingredients market is segmented on the basis of:
Types
Monoclonal Antibodies, Hormones, Cytokines, Fusion Proteins, Therapeutic Enzymes, Vaccines, Blood Factors
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncology, Diabetes, Cardiovascular Disease, CNS and Neurological Disorders, Endocrinology, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer, Inc. (U.S.)
- Novartis International AG (Switzerland)
- Sanofi (France)
- Boehringer Ingelheim (Germany)
- Bristol-Myers Squibb (U.S.)
- Teva Pharmaceutical Industries Ltd. (Israel)
- Eli Lilly and Company (U.S.)
- GlaxoSmithKline plc (U.K.)
- Merck & Co., Inc. (U.S.)
- AbbVie Inc. (U.S.)
- Pfizer, Inc. (U.S.)
Highlights of The Generic Active Pharmaceutical Ingredients Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Monoclonal Antibodies
- Hormones
- Cytokines
- Fusion Proteins
- Therapeutic Enzymes
- Vaccines
- Blood Factors
- By Application:
- Oncology
- Diabetes
- Cardiovascular Disease
- CNS and Neurological Disorders
- Endocrinology
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Generic Active Pharmaceutical Ingredients Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Generic active pharmaceutical ingredients (APIs) are chemical compounds that have been approved by the Food and Drug Administration (FDA) as interchangeable for use in medications. Generic APIs are typically more affordable than brand-name APIs, since they do not require costly research and development.
Some of the key players operating in the generic active pharmaceutical ingredients market are Pfizer, Inc. (U.S.), Novartis International AG (Switzerland), Sanofi (France), Boehringer Ingelheim (Germany), Bristol-Myers Squibb (U.S.), Teva Pharmaceutical Industries Ltd. (Israel), Eli Lilly and Company (U.S.), GlaxoSmithKline plc (U.K.), Merck & Co., Inc. (U.S.), AbbVie Inc. (U.S.), Pfizer, Inc. (U.S.).
The generic active pharmaceutical ingredients market is expected to grow at a compound annual growth rate of 6.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Generic Active Pharmaceutical Ingredients Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Generic Active Pharmaceutical Ingredients Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Generic Active Pharmaceutical Ingredients Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Generic Active Pharmaceutical Ingredients Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Generic Active Pharmaceutical Ingredients Market Size & Forecast, 2020-2028
4.5.1 Generic Active Pharmaceutical Ingredients Market Size and Y-o-Y Growth
4.5.2 Generic Active Pharmaceutical Ingredients Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Monoclonal Antibodies
5.2.2 Hormones
5.2.3 Cytokines
5.2.4 Fusion Proteins
5.2.5 Therapeutic Enzymes
5.2.6 Vaccines
5.2.7 Blood Factors
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Oncology
6.2.2 Diabetes
6.2.3 Cardiovascular Disease
6.2.4 CNS and Neurological Disorders
6.2.5 Endocrinology
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Generic Active Pharmaceutical Ingredients Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Generic Active Pharmaceutical Ingredients Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Monoclonal Antibodies
9.6.2 Hormones
9.6.3 Cytokines
9.6.4 Fusion Proteins
9.6.5 Therapeutic Enzymes
9.6.6 Vaccines
9.6.7 Blood Factors
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Oncology
9.10.2 Diabetes
9.10.3 Cardiovascular Disease
9.10.4 CNS and Neurological Disorders
9.10.5 Endocrinology
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Monoclonal Antibodies
10.6.2 Hormones
10.6.3 Cytokines
10.6.4 Fusion Proteins
10.6.5 Therapeutic Enzymes
10.6.6 Vaccines
10.6.7 Blood Factors
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Oncology
10.10.2 Diabetes
10.10.3 Cardiovascular Disease
10.10.4 CNS and Neurological Disorders
10.10.5 Endocrinology
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Monoclonal Antibodies
11.6.2 Hormones
11.6.3 Cytokines
11.6.4 Fusion Proteins
11.6.5 Therapeutic Enzymes
11.6.6 Vaccines
11.6.7 Blood Factors
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Oncology
11.10.2 Diabetes
11.10.3 Cardiovascular Disease
11.10.4 CNS and Neurological Disorders
11.10.5 Endocrinology
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Monoclonal Antibodies
12.6.2 Hormones
12.6.3 Cytokines
12.6.4 Fusion Proteins
12.6.5 Therapeutic Enzymes
12.6.6 Vaccines
12.6.7 Blood Factors
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Oncology
12.10.2 Diabetes
12.10.3 Cardiovascular Disease
12.10.4 CNS and Neurological Disorders
12.10.5 Endocrinology
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Monoclonal Antibodies
13.6.2 Hormones
13.6.3 Cytokines
13.6.4 Fusion Proteins
13.6.5 Therapeutic Enzymes
13.6.6 Vaccines
13.6.7 Blood Factors
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Oncology
13.10.2 Diabetes
13.10.3 Cardiovascular Disease
13.10.4 CNS and Neurological Disorders
13.10.5 Endocrinology
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Generic Active Pharmaceutical Ingredients Market: Competitive Dashboard
14.2 Global Generic Active Pharmaceutical Ingredients Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer, Inc. (U.S.)
14.3.2 Novartis International AG (Switzerland)
14.3.3 Sanofi (France)
14.3.4 Boehringer Ingelheim (Germany)
14.3.5 Bristol-Myers Squibb (U.S.)
14.3.6 Teva Pharmaceutical Industries Ltd. (Israel)
14.3.7 Eli Lilly and Company (U.S.)
14.3.8 GlaxoSmithKline plc (U.K.)
14.3.9 Merck & Co., Inc. (U.S.)
14.3.10 AbbVie Inc. (U.S.)
14.3.11 Pfizer, Inc. (U.S.)
